» Articles » PMID: 36934088

SARS-CoV-2 Spike-ferritin-nanoparticle Adjuvanted with ALFQ Induces Long-lived Plasma Cells and Cross-neutralizing Antibodies

Abstract

This study demonstrates the impact of adjuvant on the development of T follicular helper (Tfh) and B cells, and their influence on antibody responses in mice vaccinated with SARS-CoV-2-spike-ferritin-nanoparticle (SpFN) adjuvanted with either Army Liposome Formulation containing QS-21 (SpFN + ALFQ) or Alhydrogel (SpFN + AH). SpFN + ALFQ increased the size and frequency of germinal center (GC) B cells in the vaccine-draining lymph nodes and increased the frequency of antigen-specific naive B cells. A single vaccination with SpFN + ALFQ resulted in a higher frequency of IL-21-producing-spike-specific Tfh and GC B cells in the draining lymph nodes and spleen, S-2P protein-specific IgM and IgG antibodies, and elicitation of robust cross-neutralizing antibodies against SARS-CoV-2 variants as early as day 7, which was enhanced by a second vaccination. This was associated with the generation of high titer, high avidity binding antibodies. The third vaccination with SpFN + ALFQ elicited high levels of neutralizing antibodies against the Omicron variant. No cross-neutralizing antibodies against Omicron were induced with SpFN + AH. These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow. The early engagement of S-2P specific naive B cells and high titer IgM antibodies shape the development of long-term neutralization breadth.

Citing Articles

Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines.

Chentoufi A, Ulmer J, BenMohamed L Vaccines (Basel). 2025; 13(1).

PMID: 39852809 PMC: 11769099. DOI: 10.3390/vaccines13010030.


Ferritin Vaccine Platform for Animal and Zoonotic Viruses.

Ahmadivand S, Fux R, Palic D Vaccines (Basel). 2024; 12(10).

PMID: 39460279 PMC: 11511493. DOI: 10.3390/vaccines12101112.


SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.

Martinez E, Chang W, Chen W, Hajduczki A, Thomas P, Jensen J iScience. 2024; 27(10):110624.

PMID: 39351195 PMC: 11440237. DOI: 10.1016/j.isci.2024.110624.


Development of semisynthetic saponin immunostimulants.

Bai D, Kim H, Wang P Med Chem Res. 2024; 33(8):1292-1306.

PMID: 39132259 PMC: 11315725. DOI: 10.1007/s00044-024-03227-x.


Application and Method of Surface Plasmon Resonance Technology in the Preparation and Characterization of Biomedical Nanoparticle Materials.

Zhang J, Liu B, Chen H, Zhang L, Jiang X Int J Nanomedicine. 2024; 19:7049-7069.

PMID: 39011388 PMC: 11249113. DOI: 10.2147/IJN.S468695.


References
1.
Alving C, Peachman K, Matyas G, Rao M, Beck Z . Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev Vaccines. 2020; 19(3):279-292. PMC: 7412170. DOI: 10.1080/14760584.2020.1745636. View

2.
Parums D . Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants. Med Sci Monit. 2022; 28:e936523. PMC: 8897963. DOI: 10.12659/MSM.936523. View

3.
Nutt S, Tarlinton D . Germinal center B and follicular helper T cells: siblings, cousins or just good friends?. Nat Immunol. 2011; 12(6):472-7. DOI: 10.1038/ni.2019. View

4.
Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

5.
Feldman J, Bals J, Altomare C, St Denis K, Lam E, Hauser B . Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Sci Immunol. 2021; 6(66):eabl5842. PMC: 8720485. DOI: 10.1126/sciimmunol.abl5842. View